scholarly journals Peer Review of “Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study” (Preprint)

2021 ◽  
Author(s):  
Keyword(s):  
Monoclonal Antibody ◽  
Survival Analysis ◽  
Peer Review ◽  
Retrospective Cohort ◽  
Antibody Therapy ◽  
Early Experience ◽  
Descriptive Study ◽  
Monoclonal Antibody Therapy ◽  
Neutralizing Monoclonal Antibody

UNSTRUCTURED This is a peer review report associated with ms#29638

scholarly journals Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic

2021 ◽  
Author(s):  
Yasuhito Suzuki ◽  
Yoko Shibata ◽  
Hiroyuki Minemura ◽  
Takehumi Nikaido ◽  
Yoshinori Tanino ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Real World ◽  
Odds Ratio ◽  
Antibody Therapy ◽  
Multivariate Logistic Regression Analysis ◽  
Monoclonal Antibody Therapy ◽  
Independent Factor ◽  
Multivariate Logistic Regression ◽  
Neutralizing Monoclonal Antibody ◽  
History Of

Background: Mutations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may reduce the efficacy of neutralizing monoclonal antibody therapy against coronavirus disease 2019 (COVID-19). We here evaluated the efficacy of casirivimab-imdevimab in patients with mild-to-moderate COVID-19 during the Delta variant surge in Fukushima Prefecture, Japan. Methods: We enrolled 949 patients with mild-to-moderate COVID-19 who were admitted to hospital between July 24, 2021 and September 30, 2021. Clinical deterioration after admission was compared between casirivimab-imdevimab users (n = 314) and non-users (n = 635). Results: The casirivimab-imdevimab users were older (P < 0.0001), had higher body temperature (≥ 38 degree) (P < 0.0001) and greater rates of history of cigarette smoking (P = 0.0068), hypertension (P = 0.0004), obesity (P < 0.0001), and dyslipidemia (P < 0.0001) than the non-users. Multivariate logistic regression analysis demonstrated that receiving casirivimab-imdevimab was an independent factor for preventing deterioration (odds ratio 0.448; 95% confidence interval 0.263 to 0.763; P = 0.0023). Furthermore, in 222 patients who were selected from each group after matching on the propensity score, deterioration was significantly lower among those receiving casirivimab-imdevimab compared to those not receiving casirivimab-imdevimab (7.66% vs 14.0%; p = 0.021). Conclusion: This real-world study demonstrates that casirivimab-imdevimab contributes to the prevention of deterioration in COVID-19 patients after hospitalization during a Delta variant surge.

scholarly journals Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections

2021 ◽  
Author(s):  
Hilal Ahmad Parray ◽  
Shivangi Shukla ◽  
Reshma Perween ◽  
Ritika Khatri ◽  
Tripti Shrivastava ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Respiratory Infections ◽  
Antibody Therapy ◽  
Monoclonal Antibody Therapy
Sign in / Sign up

Export Citation Format

Share Document